Genzeva is a Fully Licensed CLIA commercial laboratory. We pride ourselves on having the highest standards for quality control.
Genzeva is the universal advanced technology solution for your genetic testing. We provide the most advanced bioinformatics platform to detect, annotate and classify genomic variants associated with multiple disorders, including heart conditions, metabolic and pediatric disorders, oncology for patients with active and hereditary cancers, and many others.
The Genzeva intelligent software solution is a specialized, secure cloud platform that leverages the analytical power of our artificial intelligence, facilitating variant visualization, interpretation and annotation of genomic variants. Using its intuitive user interface and integrated features, it assures protection of all the data by encrypting them to our high security standards before storing the data redundantly in secured and private data centers.
The NovaSeq 6000 is ideal for next-generation sequencing projects of DNA or RNA with unparalleled sequencing efficiency.
The Agena MassArray is used for pharmacogenomics, tumor profiling, liquid biopsy, sample integrity, specimen validity, hereditary genetics, methylation, and chimerism.
Genzeva is a Certified Service Provider
Achieve Unparalleled Structural Variant Detection using our Optical Genome Mapping Technology. Routinely detect all classes of structural variants down to 500 base pair (bp) resolution and 5% variant allele frequency (VAF) with optical genome mapping (OGM) using the Saphyr system. Saphyr is the most powerful structural variant detection tool available, detecting genomic variants commonly missed by next-generation sequencing (NGS) technologies and conventional cytogenetic techniques.
The use of a specialized form of artificial intelligence and Digital Twin Ecosystems in genomic medicine, using newfound methodologies which are on the cusp of revolutonizing precision medicine and drug development.
Dr. William G. Kearns is an internationally renowned expert and leader in the field of genomic medicine who currently serves as Co-Founder/CEO and Chief Scientific Officer of two companies on the forefront of groundbreaking advancements, Genzeva and LumaGene.
With a wealth of experience and an unwavering dedication to innovation, Kearns is a trusted authority and visionary behind the most advanced bioinformatics platforms that detect, annotate, and classify genomic variants associated with multiple disorders, including heart conditions, metabolic and pediatric disorders, oncology for patients with active and hereditary cancers, and many others.